Verano Holdings Past Earnings Performance
Past criteria checks 0/6
Verano Holdings's earnings have been declining at an average annual rate of -46.3%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 28.5% per year.
Key information
-46.3%
Earnings growth rate
-75.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 28.5% |
| Return on equity | -12.0% |
| Net Margin | -16.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Are Investors Undervaluing Verano Holdings Corp. (CSE:VRNO) By 31%?
Oct 07
Why Investors Shouldn't Be Surprised By Verano Holdings Corp.'s (CSE:VRNO) 34% Share Price Surge
Sep 02An Intrinsic Calculation For Verano Holdings Corp. (CSE:VRNO) Suggests It's 27% Undervalued
Jan 26Verano Holdings Corp. (CSE:VRNO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 12Verano Holdings' (CSE:VRNO) Earnings Are Weaker Than They Seem
May 25Revenue & Expenses Breakdown
How Verano Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 898 | -146 | 340 | 0 |
| 30 Jun 24 | 921 | -122 | 334 | 0 |
| 31 Mar 24 | 933 | -113 | 331 | 0 |
| 31 Dec 23 | 938 | -117 | 316 | 0 |
| 30 Sep 23 | 927 | -256 | 315 | 0 |
| 30 Jun 23 | 915 | -281 | 314 | 0 |
| 31 Mar 23 | 904 | -278 | 330 | 0 |
| 31 Dec 22 | 879 | -269 | 344 | 0 |
| 30 Sep 22 | 865 | -60 | 357 | 0 |
| 30 Jun 22 | 844 | -30 | 348 | 0 |
| 31 Mar 22 | 819 | -50 | 318 | 0 |
| 31 Dec 21 | 738 | -58 | 271 | 0 |
| 30 Sep 21 | 600 | -135 | 206 | 0 |
| 30 Jun 21 | 458 | -35 | 141 | 0 |
| 31 Mar 21 | 307 | 10 | 77 | 0 |
| 31 Dec 20 | 229 | 38 | 43 | 0 |
| 30 Sep 20 | 179 | 127 | 33 | 0 |
| 31 Dec 19 | 66 | -18 | 37 | 0 |
| 31 Dec 18 | 31 | -1 | 10 | 0 |
Quality Earnings: VRNO is currently unprofitable.
Growing Profit Margin: VRNO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VRNO is unprofitable, and losses have increased over the past 5 years at a rate of 46.3% per year.
Accelerating Growth: Unable to compare VRNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: VRNO has a negative Return on Equity (-12.03%), as it is currently unprofitable.